Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biotron Ltd
ASX:BIT
|
AU |
|
G
|
Grand Baoxin Auto Group Ltd
OTC:GBXXY
|
CN |
|
K
|
Kakatiya Textiles Ltd
BSE:521054
|
IN |
|
S
|
SBFC Finance Ltd
BSE:543959
|
IN |
|
M
|
MAG Holdings Berhad
KLSE:MAGNUM
|
MY |
|
Innovent Biologics Inc
HKEX:1801
|
CN |
|
Universal Health Services Inc
NYSE:UHS
|
US |
|
MarineMax Inc
NYSE:HZO
|
US |
|
Indigo Paints Ltd
NSE:INDIGOPNTS
|
IN |
|
Fukuoka Financial Group Inc
OTC:FKKFY
|
JP |
|
Ramayana Lestari Sentosa Tbk PT
IDX:RALS
|
ID |
Biotron Ltd
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
